Effect of a specific endothelin A receptor antagonist on marine lupus nephritis. The present study was designed to assess whether a specific endothelin A (ETA) receptor antagonist, FR139317, affects the progression of lupus ncphritis and affects transcription of mRNA for extracellular matrix (ECM) components, metalloproteinases (MMPs) and tissue inhibitor of metalloproteinase (TIMP)-l, and accumulation of ECM proteins in the renal cortex of NZB/W Fl mice. mRNA levels for al(I), al(III), al (IV) collagen chains, laminin Bi and B2 chains, heparan sulfate proteoglycan (HSPG), MMP-1, -2, -3, and TIMP-1 increased significantly as nephritis progressed in NZB/W Fl mice. At 48 weeks of age, the levels of mRNA for al(I), al(III), al(IV) collagen chains, laminin Bi and B2 chains, HSPG, MMP-1, -2, -3, and TIMP-1 were increased by 5.6-(P C 0.001), 3.6-(P < 0.01), 6.8-(P cc 0.001), 5.2-(P cc 0.001), 5.0-(P cc 0.001), 6.0-(P cc 0.001), 7.6-(P cc 0.001), 4.2-(P cc 0.01), 8.2-(P cc 0.001), and 15.2-fold (P cc 0.001), respectively, in the renal cortex of NZB/W Fl mice compared to NZW mice. Immunofiuorescence microscopy showed that the accumulation of collagens I, III, and IV, laminin, and HSPG in the renal cortex of NZB/W Ft mice increased markedly with the progression of nephritis. At 20 weeks of age, NZB/W Fl and NZW mice were divided into two groups that received either FR139317 or its vehicle (saline) intraperitoneally, daily, for 28 weeks. The development of histological lesions, proteinuria, hypertension, accumulation of collagens I, III, and IV, laminin, and HSPG in the renal cortex of NZBIW Fl mice were suppressed by FR139317 treatment. Levels of mRNA for ECM components, MMPs, and TIMP-1 in the renal cortex of NZB/W Fl mice were ameliorated significantly by FR139317 administration. There data suggest that FR139317 treatment can be used therapeutically to regulate the expression of ECM components, MMPs, and TIMP-1 in murine lupus nephritis.
The present study was designed to investigate whether FR139317 prevented the renal injury in NZB/W Fl mice, and whether this compound attenuated ECM accumulation and the abnormally high mRNA expression of ECM components, MMPs, and TIMP-l in the renal cortex of NZB/W Fl mice.
Methods

Animals
Two hundred six-week-old female NZB/W Fl mice and 100 age-matched NZW mice were obtained from Charles River, Inc. (Atsugi, Kanagawa, Japan) and maintained at the mouse unit of Juntendo University on standard laboratory chow. Ten mice from each strain were killed by cervical dislocation at 8, 32, or 48 weeks after birth. The kidneys were removed immediately from the surrounding peritoneal fat and were sectioned longitudinally. At 20 weeks of age (just before nephritis developed), NZB/W Fl mice and NZW mice were assigned randomly to a treated or untreated group. We injected NZB/W Fl mice and NZW mice intraperitoneally with the specific ETA receptor antagonist, FR139317 (Fujisawa Pharmaceutical Co. Ltd., Osaka, Japan) [8, 10] daily at a dose of 3.2 mg/100 g for 28 weeks. FR139317 specifically binds ETA receptor binding sites, as documented in vitro by concentration-dependent inhibition of the binding of labeled ET-1 to porcine and human aortic microsomes with an IC50 in the nanomolar range [11] . In vivo a single bolus dose of FR139317 completely inhibited the pressor response to ET-1, but had no effect on the initial depressor response due to ET-3 in conscious normotensive rats [11] . Untreated NZB/W Fl mice and NZW mice were injected daily with saline for 28 weeks. The cortex of the sectioned kidney was either frozen rapidly in liquid nitrogen for immunohistochemistry and RNA extraction of the cortex or fixed for light microscopy. Freshly voided urine specimens from each animal was tested with standard uropaper (Eiken Chemical Co., Tokyo, Japan) at 8, 32, and 48 weeks of age. Animals were considered to have developed proteinuria when their urinary protein concentration exceeded 300 mg/dl (3+) [3, 4] .
Renal function
Glomerular filtration rate (GFR) was measured as the clearance of inulin as described by Kiberd [1, 12] . C14 inulin-loaded (50 sCi) osmotic minipumps were placed intraperitoneally under pentobarbital anesthesia. Twenty-four hours later, ten consecutive 24-hour urine collections were begun, with plasma samples taken by retro-orbital puncture bracketing the urine collections. Urine and plasma C14 was measured by scintillation spectrometry. GFR was calculated from urine and plasma C14 counts and urine flow rates.
Blood pressure measurement
Indirect systolic blood pressure was measured with a photoelectric tail cuff connected to a pulse amplifier and manometer [13] . The unanesthetized mice were placed in plastic holders, and their tails were warmed with a floodlight while their bodies were shielded with aluminum foil.
Light microscopic studies
For light microscopic examination, the renal tissues were fixed in 10% buffered formalin and embedded in paraffin. Renal sections (4 tim) were stained with hematoxylin and eosin and periodic acid-Schiff. For each specimen (10 mice), 30 glomeruli were examined and the histopathology was graded arbitrarily graded according to the following criteria [14] : 0, normal; 1+, mild mesangial cell and matrix proliferation; 2+, more extensive mesangial proliferation; 3+, diffuse glomerular proliferation with basement membrane thickening; and 4+, all of the above changes associated with wire loop lesions, glomerular sclerosis, and interstitial fibrosis. In addition, we scored the degree of interstitial nephritis [15] . Mononuclear cell infiltrates around renal arteries were graded on a scale of 0 to 4+: 0, no lymphocytes; 1, few lymphocytes; 2, lymphocytes surrounding 25% to 50% of the arterial wall; 3, lymphocytes surrounding 75% of the arterial wall; and 4, lymphocytes surrounding the entire artery.
Immunohistochemical studies
Immunofluorescence staining of renal tissues was performed by our previously described method [16] . In brief, renal cryostat sections were stained with fluorescein isothiocyanate (FITC)conjugated rabbit anti-mouse gamma G immunoglobulin (IgG), 1gM, C3 (Cappel Laboratories, Malvern, PA, USA) (1:32). Rabbit antibodies to mouse laminin, collagen IV, and HSPG, prepared as described previously [17, 18] (1:16), were provided by Drs. Hynda Kleinman and John Hassell, National Institute of Dental Research (Bethesda, MD, USA). Monospecific antibodies raised against rat type I and III collagens were provided by Dr. Akira Ooshima, Wakayama Medical College (Wakayama, Japan) [19] (1:16). Fluorescein isothiocyanate-conjugated goat anti-rabbit IgG was purchased from Cappel Laboratories. Renal sections (4 were incubated with various antibodies after the second incubation with FITC-conjugated anti-rabbit IgG antibodies. The relative amount of staining was scored semiquantitatively from 0 to 5: 0, no staining; 1, trace staining; 2, slight staining; 3, moderate staining; 4, intense staining; and 5, most intense staining. The scores were calculated by averaging the staining score in 20 glomeruli in each group of 10 mice. In addition, the scores of types I and III collagen were calculated in interstitial areas in 10 mice.
Extraction and quantitation of cellular RNA
The renal cortices were separated from medulla from 10 NZB/W Fl mice and 10 NZW mice with or without FR139317 treatment, and frozen separately in liquid nitrogen for RNA extraction at each time point. Total cellular RNA was extracted from renal cortices by the acid guanidinium thiocyanate-phenolchloroform extraction method [20] . The total RNA concentration was determined spectrophotometrically at 260 nm. The purity of the RNA preparation was assessed by measuring the ratio of absorbance at 260 to that at 280 nm. RNA samples (20 tg) were denatured and electrophoresed through 0.7% agarose gels containing 2.2 mol/liter formaldehyde and were then transferred by capillary blotting onto nylon filters (GeneScreen, New England Nuclear, Boston, MA, USA). Before transferring RNA onto nylon membranes, ethidium-stained gels were visualized under ultraviolet illumination to determine the position of the 28S and 18S ribosomal RNA bands so as to assess the integrity of the RNA, and to verify that equal amounts of RNA were loaded in each lane. The membrane was air-dried, then baked at 80° for two hours. The membrane was hybridized at 65°C for 16 hours in 5X SSC (1X SSC=0.15 mol/l NaC1, 0.015 mol/liter sodium citrate), 50% formamide, lx Denhardt's solution (0.02% polyvinylpyrrolidone, 0.02% Ficoll and 0.02% BSA) and 1% sodium dodecyl sulfate (SDS) containing 100 g/ml denatured salmon sperm DNA. The membrane was washed in 2X SSC at room temperature for five minutes, followed by 2X SSC containing 1% SDS at 65°C for 30 minutes, and 0.1X SSC at room temperature for another 30 minutes. The filter was then exposed to Kodak X-OMAT-AR film (Eastman-Kodak, Rochester, NY, USA) at -70° with the aid of intensifying screens. Multiple exposures were scanned with a Shimadzu CS-9000 densitometer (Shimadzu Manufacturing, Kyoto, Japan) to determine the linear range. cDNA probes The cDNA probes used for Northern analysis were prepared as follows. Clones for the al(IV) collagen chain (pFAC), laminin Bi (p24) and B2 (p7) chains were isolated from a cDNA library constructed from differentiated F9 teratocarcinoma cell mRNA, as reported previously [21, 22] . Heparan sulfate proteoglycan (clone 7), rat cvl(I) (paiRl) and al(III) (1.8 Kb EcoRl fragment) collagen cDNA probes were provided by Dr. Yoshihiko Yamada, National Institute of Dental Research [23] [24] [25] [26] . Rat MMP-1 and MMP-3 cDNA probes were provided by Dr. Lynn M. Matrisian, Vanderbilt University (Nashville, TN, USA) [27, 28] . The cDNA probe for human MMP-2 was provided by Dr. Gregory I. Goldberg and Barry L. Marmer, Washington University School of Medicine (St. Louis, MO, USA) [29, 30] . Human TIMP-1 cDNA was provided by Dr. Masanobu Naruto, Basic Research Laboratories, Toray Industries (Kanagawa, Japan) [31] . The rat GAPDH cDNA was obtained from the American Type Culture Collection (Rockville, MD, USA). The cDNA inserts were excised and labeled using a random-primed cDNA labeling kit (Boehringer-Mannheim-Yamanouchi K.K., Tokyo, Japan) with 32P-labeled deoxynucleotides (New England Nuclear) to a specific activity of iO cpm/sg [32] .
Statistical analysis
The quantitative densitometric measurements on the Northern blots were normalized to the signal for GAPDH mRNA. Values Animals were considered to have developed proteinuria when the urinary protein concentration was more than 300 mg/dl (3+). Values are means SE. a P < 0.01 compared with untreated NZB/W Fl mice mice with or without FR139317 administration, GFR showed little change throughout the experimental periods ( Table 2 ).
Blood pressure
The blood pressure is shown in Table 3 . NZW mice with or without FR139317 had no evidence of hypertension. The blood pressure in NZB/W Fl mice increased with age (8 weeks, 84 5 mm Hg; 32 weeks, 116 8 mm Hg; 48 weeks, 162 12 mm Hg). FR139317 reduced the increase in blood pressure (32 weeks, 98 6 mm Hg; 48 weeks, 128 10 mm Hg).
Light microscopy
No distinctive pathological changes were observed by light microscopy in NZW mice treated with or without FR139317 up to 48 weeks of age. In untreated NZB/W Fl mice, proliferation of glomerular cells and thickening of the mesangial matrix were observed at 32 weeks of age. Glomerular lobulation, fibrinoid necrosis, crescent formation, severe mesangial expansion and glomerulosclerosis were observed at 48 weeks of age. The renal tubules were also severely damaged and dilated with casts. A striking feature was infiltration by mononuclear cells between calices, and in the renal interstitium and surrounding blood vessels. FR139317 ameliorated these histopathological changes, including glomerular volume, mesangial proliferation and infiltration by mononuclear cells (Fig. 1) . The histopathological scores of NZB/W Fl mice and NZW mice with or without FR139317 treatment are shown in Table 4 .
Immunofluorescence microscopy
No deposits of IgG, 1gM or C3 were detected in the glomeruli of NZW mice regardless of FR139317 administration throughout the experiments. IgG, 1gM, and C3 were deposited in the mesangial areas of NZB/W Fl mice at 32 weeks of age. This deposition was increased and extended to the glomerular capillary walls by 48 weeks of age. The amount of immunoreactants in the glomeruli was decreased by treatment with FR139317.
At 32 weeks of age, thickened capillary loops, thickened tubular basement membranes and expanded mesangial matrix showed increased staining for type IV collagen, laminin, and HSPG in the kidneys of NZB/W Fl mice. At 48 weeks of age, the distribution and intensity of these components was increased significantly in the glomeruli of NZB/W Fl mice when compared to the findings at 32 weeks of age. The distribution and intensity of type IV collagen, laminin, and HSPG in kidneys of NZBIW Fl mice were decreased by treatment with FR139317 ( Fig. 2) . Immunofiuorescence scores for type IV collagen, laminin and HSPG in the and increased amounts were observed in the glomeruli and interstitium as the nephritis progressed. The amounts of type I and III collagens in the glomeruli and interstitium were decreased by FR139317 administration (Fig. 3) . Immunofluorescence scores for type I and III collagens in the glomeruli and interstitium of NZB/W Fl mice with or without FR139317 treatment are shown in Table 6 . Figure 5 shows Northern blots of mRNA for MMP-1, -2, -3, and TIMP-1 in the kidney of untreated NZB/W Fl mice. Table 8 shows the relative changes of mRNA for these proteins. mRNA levels for MMP-1, In the present study, we demonstrated that a specific ETA receptor antagonist ameliorated lupus nephritis and abnormally increased expression of mRNA for ECM components, MMPs, and TIMP-1. Recently, some investigators reported that an interleukin-6 receptor blocker, or anti-interleukin 10 antibody, ameliorated murine lupus nephritis [34, 35] . Benigni et al [8] showed that the ETA receptor antagonist protects against injury in remnant kidneys. However, little is known about the effect of ETA receptor antagonist on the regulation of ECM component, MMPs and TIMP-1 genes in kidney of lupus mice.
Some investigators reported that lupus mice became severely hypertensive with the progression of nephritis [13, 36] . It was suggested that a reduction of the glomeriilar filtration rate (GFR) by immune complex deposition ought to increase blood pressure.
Kiberd showed that the GFR fell in NZB/W Fl mice with the progression of nephritis [1, 12] . Our data coincided with them. FR139317 reduced systemic blood pressure and ameliorated GFR in NZBIW Fl mice. Since systemic hypertension has a negative impact on renal disease progression [37, 38] , the question arises whether the beneficial effect was due to antihypertensive actions of FR139317. Some effect on the local determinants of renal injury may be assumed to explain the renoprotective effect of ETA receptor blocking [39] . It is unclear whether FR139317 ameliorates intraglomerular capillary hypertension in lupus nephritis in the present study. In the preliminary study, we examined whether angiotensin converting enzyme inhibitor, enalapril, have a similar beneficial effect on gene expression of ECM components, MMPs, and TIMP-1 in lupus nephritis. Enalapril reduced systemic hypertension, whereas it had little effect on gene expression of all these proteins examined (Nakamura T, et al, unpublished data). Therefore, the beneficial effect may not only be due to antihypertensive actions of antagonizing ETA receptor. Since we showed that FR139317 ameliorated the GFR in lupus mice, our data may be due to secondary to improvement in renal hemodynamics rather than to a direct effect on structural changes described. Chan et al demonstrated that the other ETA receptor antagonist, BQ123, has a protective effect in the acute renal failure model as assessed by GFR [9] . Proliferation of intrinsic glomerular mesangial cells as well as expansion of the mesangial extracellular matrix (ECM) are central features of numerous glomerular diseases including lupus nephritis. These processes play a pivotal role in the development of glomerular sclerosis and renal failure [401. Given the complex composition of the ECM, it is postulated that an extensive spectrum of MMPs and TIMP-1 is involved in the turnover of the ECM, particularly within the glomerular mesangium. The accumulation of ECM results from a balance between synthetic and degradative processes. The rate of ECM degradation probably correlates with the relative levels of MMPs and TIMP. Our data suggest that the enhanced expression of mRNA for ECM components, MMPs, and TIMP-1 may contribute to the evolution of renal injury in lupus nephritis. We previously demonstrated that the renal concentrations of ET-1, ETA and ETB receptor mRNAs increased significantly with age in NZB/W Fl mice and that those of ET-3 mRNA did not change throughout the experimental period [5] .
A selective high-affinity ET receptor is the A receptor [41] . A less selective ETB receptor has been identified [42] . The ETA receptor mediates vasoconstriction and smooth muscle cell proliferation, while the function of the ETB receptor is not fully defined [43] . A role for enhanced endothelin expression in renal disease progression is suggested by recent evidence of mesangial cell proliferation and ECM protein synthesis in response to endothelin [43, 44] . ETA receptor-linked phosphoinositide hydrolysis acts as the signal event for up-regulating phospholipase C-mediated c-fos and c-myc oncogenes [45, 46] . These intracellular events are consistently associated with cell proliferation [47] .
Proliferating cell nuclear antigen (PCNA) is an intranuclear polypeptide whose expression and synthesis is linked to cell proliferation [48] . We previously reported that NZB/W Fl mice showed with age a significant increase of mRNA for PCNA [49] .
We also recognized that mRNA for c-myc, c-fos, and c-jun Values are expressed as optical density units relative to the specific mRNA levels observed in mRNA from untreated NZW control mice.
Values are means SE. a P C oo, b P C 0.01 for untreated NZB/W Fl mice compared with FR139317-treated NZB/W Fl mice and that FR139317 suppressed the up-regulation of these protooncogenes and PCNA expression in NZB/W Fl mice (Nakamura T, et al, unpublished data). We previously reported that mRNA levels for growth factors including platelet-derived growth factor (PDGF), transforming growth factor (TGF)-f3, are increased markedly with age in kidneys of NZB/W Fl mice [49, 50] . TGFand TNF-a have been shown to stimulate ET-1 mRNA and protein in glomerular cells [51, 52] . Recently, Kohno et al [53] reported that ET-1 production is increased by PDGF in mesangial cells and that PDGF stimulate mitogenesis of these cells, at least in part, by increasing endogenous ET-1 production. These growth factors may lead to increased ET-1 synthesis in ETA receptor activation. We recognized that levels of mRNA for these growth factors in kidneys of NZB/W Fl mice are suppressed by treatment with FR139317 (Nakamura T, et al, unpublished data). Therefore, it may be speculated that blocking ETA receptors would limit the biological consequences of growth factor-induced up-regulation of genes encoding ECM components [54] , thereby reducing a major component of glomerular sclerosis [55] . Given the fact that the ETB receptor mRNA is expressed in glomeruli [56, 57] , the potential role of ET receptor antagonist in suppressing the progression of lupus nephritis cannot be excluded. In a preliminary study, however, we recognized that the ET receptor antagonist did not ameliorate lupus nephritis or abnormally regulated ECM gene expression (Nakamura T, et al, unpublished data).
Therefore, the ETA receptor antagonist specifically reduced lupus nephritis.
In summary, severe lupus nephritis is reversed by the selective ETA receptor antagonist, FR139317, by significantly improving abnormally regulated ECM gene expression. Our data may be of clinical importance, as it suggests a possible therapeutic approach for retarding the progression of lupus nephritis. 
